APR 02, 2020 5:40 AM PDT

Diagnosing Cancer: SMOC2 and Thyroid Cancer

WRITTEN BY: Jasper Cantrell

Thyroid cancer is the most common of the endocrine cancers, with papillary thyroid carcinomas (PTCs) being the most common form. Thyroid cancer has excellent diagnostic tools, yet there are still some cases that progress post treatment and a few that are not caught at all. A group from Jeju, South Korea decided to investigate SPARC-related modular calcium-binding protein-2, or SMOC2, as a potential tool for further diagnostic tests to catch recurrence early on.

SMOC2, usually a regulator of a cell’s interaction with the surrounding environment during development or disease, has been implicated in several processes related to the progression of cancer. Using this information, the group began to measure the levels of SMOC2 expression in normal thyroid tissue versus PTC thyroid tissues.

The group began by using reverse transcription PCR to measure the mRNA encoding SMOC2 in normal thyroid tissue against several forms of thyroid cancer. They found that SMOC2 expression was lower in almost every cancer sample compared to normal thyroid samples. Next, they took a large sample size of 338 PTC samples and directly stained for SMOC2. The results, showing a significantly lower level of SMOC2 in PTC samples compared to regular thyroid samples, which concurred with the previous mRNA measurements.

Unfortunately, not every result was as clear cut. The thyroid cancer nodular hyperplasia did not follow the same trend rest of the thyroid cancers, retaining normal levels of SMOC2 expression. Follicular adenomas also failed to produce statistically significant data in SMOC2 expression testing. The group tried to investigate why SMOC2 would be down regulated in PTCs, looking at epigenetic methylation of SMOC2's DNA. The sample sized proved to be to small however, and again could not produce much statistically significant data.

The group concludes “Our findings of SMOC2 expression down-regulation in PTC and its association with improved clinical outcomes clearly suggest that SMOC2 likely acts as a tumor suppressor in thyroid cancers.”. Even though some of the results proved inconclusive, the work done here showed productive insights for the possible use of SMOC2 as a secondary biomarker in tests against thyroid cancer.

Sources: Nature, OncLive

About the Author
  • Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
JUL 26, 2020
Cannabis Sciences
Medicinal Cannabis Kills Cancer Cells
JUL 26, 2020
Medicinal Cannabis Kills Cancer Cells
Researchers at the University of Newcastle have found that a modified version of medicinal cannabis can kill and inhibit ...
JUL 26, 2020
Cancer
Diet confirmed to be linked to prostate cancer risk
JUL 26, 2020
Diet confirmed to be linked to prostate cancer risk
A study published in Nutrients earlier this summer points toward diet as a key risk factor for prostate cancer ...
AUG 28, 2020
Cancer
Using CRISPR-Cas12a to Repair Hereditary Cancers in the Lab
AUG 28, 2020
Using CRISPR-Cas12a to Repair Hereditary Cancers in the Lab
Genome repair is one of the big-ticket research areas for the future of medicine. CRISPR-Cas9 systems can edit the genom ...
SEP 11, 2020
Cancer
Targeting Senescence in the Peripheral Nervous System to Fight Toxicity
SEP 11, 2020
Targeting Senescence in the Peripheral Nervous System to Fight Toxicity
Chemotherapy is a life-saving discovery for cancer patients. One of its biggest drawbacks is the toxicity that comes wit ...
SEP 08, 2020
Cancer
The story of a very scary protein
SEP 08, 2020
The story of a very scary protein
New research from biochemists at the University of Alberta has identified a protein that triggers the growth of aggressi ...
SEP 21, 2020
Cancer
The Protein ETV1 May Act as a Biomarker for Gastrointestinal Cancer
SEP 21, 2020
The Protein ETV1 May Act as a Biomarker for Gastrointestinal Cancer
Cancer is an incredibly diverse disease. It has many types and even sub-types, with a vast range of characteristics. Som ...
Loading Comments...